Print Page | Sign In | Join ISSX
From Studentship to Early Career Professional: Navigating the Transition from Academia to Industry
Share |

ISSX Webinar: From Studentship to Early Career Professional: Navigating the Transition from Academia to Industry

Panelists: Tom Baillie, Ph.D., University of Washington; Kathy Giacomini, Ph.D., UCSF; Valerie Kramlinger, Ph.D., Novartis; and David Stresser, Ph.D., AbbVie
Friday, August 14, 2020

View the Recording


Graduate students face several challenges with navigating today’s job market due to insufficient information and/or guidance on how to make a successful industry transition. Join ISSX New investigators Webinar to discuss how you can identify several industry career paths, and understand the necessary steps required for making an effective industry transition. In this webinar, our industry and academic experts will provide practical advice on how to navigate the industry job market covering topics including: acquiring relevant skills, trainings, and professional affiliations; job opportunities in the pharmaceutical industry; how to navigate the job market during a pandemic, and putting together a winning job application that meets the needs of your future employer. Participants will also have the opportunity to ask questions to our industry and academic experts.

About the Panelists:

  Thomas A. Baillie is Dean Emeritus of the School of Pharmacy at the University of Washington in Seattle, WA, where he also served as Vice Provost for Strategic Initiatives. He was born in Scotland and educated at the University of Glasgow, where he earned B.Sc. (Hons) and Ph.D. degrees in Chemistry in 1970 and 1973, respectively. He also holds a M.Sc. degree in Biochemistry from the University of London (1978) and was awarded the degree of D.Sc. in Chemistry from the University of Glasgow in 1992. Dr. Baillie’s research interests center on the application of mass spectrometry and allied techniques to mechanistic studies on the metabolism of foreign compounds, with particular emphasis on the generation of chemically-reactive, potentially toxic products of biotransformation. He has co-authored over 250 peer-reviewed publications, serves on the Advisory Boards of a number of journals and academic research centers, and acts as a consultant to several companies in the pharmaceutical and biotechnology industries. In 2014, he was the recipient of the North American Scientific Achievement Award from ISSX. From 2018-2019, Dr. Baillie served as President of the International Society for the Study of Xenobiotics (ISSX).
  Kathy Giacomini, a professor in the School of Pharmacy at the University of California, San Francisco, is a leader in the field of membrane transporters with a focus on genetic polymorphisms. In genomewide association studies she and her team discovered genetic variants in transporters associated with response to the anti-diabetic drug, metformin and to the anti-gout medication, allopurinol. She cloned, characterized and discovered the endogenous role of the human xenobiotic transporter, OCT1 (SLC22A1), and recently de-orphaned SLC22A24, an anion exchanger that preferentially transports steroid glucuronide conjugates.  Together with others, she co-founded the International Transporter Consortium, which has published highly impactful papers informing regulatory policy.  She is the Co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation and of the NIH’s Pharmacogenomics Research Network hub, PGRN-Hub.  She has received numerous awards and is an elected member of the National Academy of Medicine.
  David Stresser is a Principal Research Scientist in the DMPK-Translational Modeling department at AbbVie. Prior to joining AbbVie in 2016, he held research, management and business development positions at Gentest Corporation, BD Biosciences and Corning Life Sciences in Woburn, MA. He received post-doctoral training in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts and graduate work in the laboratories of David E. Williams and George S. Bailey at Oregon State University in Corvallis, OR, receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored > 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies, and universities.
  Valerie Kramlinger is a principal scientist in the department of Pharmacokinetic Scineces at Novartis Institute for Biomedical Sciences. She earned her Ph.D. in Biochemistry from The University of Minnesota (2013) under Prof. Sharon E. Murphy and carried out postdoctoral research at Vanderbilt University under Prof. F. Peter Guengerich before joining the pharmaceutical industry in 2016. Her research interests primarily focus on mechanistic drug metabolism, application of in vitro approaches to study drug metabolism, prediction of human pharmacokinetics and drug interactions, mechanisms of cytochrome P450 catalysis and other biotransformation reactions, and generation of chemically reactive metabolites. In addition to her current position at Novartis, Valerie is passionate about bridging the academic/industry divide in drug discovery and development by delivering university lectures and participating in outreach events for graduate students and postdocs who are interested in the pharmaceutical industry.